Verkazia reduced most symptoms of vernal keratoconjunctivitis (VKC) as early as month 11,2

Verkazia was tested against its cationic ophthalmic emulsion in clinical trials1

background image
background image mobile
1200ms
Verkazia demonstrated substantial reductions in multiple symptoms

Verkazia delivered substantial reductions in itching scores as early as month 11 

Verkazia demonstrated consistent reductions in itching scores month over month1

57% mean reduction of itching score from baseline at month 41

See reductions in itching scores from baseline over 4 months

57% mean reduction of itching score from baseline at month 41

See reductions in itching scores from baseline over 4 months

Itching score at each visit was measured using a Visual Analogue Scale (0=no itch to 100=maximal itch).

Verkazia effectively treats itching
Verkazia effectively treats itching

Verkazia delivered substantial reductions in keratitis scores as early as month 11 

Verkazia demonstrated consistent reductions in keratitis scores month over month1

53% mean reduction from baseline in CFS scores at month 41

See reduction in keratitis scores from baseline over 4 months

53% mean reduction from baseline in CFS scores at month 41

See reduction in keratitis scores from baseline over 4 months

Corneal fluorescein staining (CFS) score was measured at each month using a 5-point scale (0=no stain, and 5=most severe staining).

Verkazia effectively treats keratitis
Verkazia effectively treats keratitis

Baseline characteristics in the pivotal trial2

Select a category

  • Verkazia
    4x/day
  • Verkazia
    2x/day
  • Cationic ophthalmic emulsion
  • Characteristic
  • Verkazia 4x/day
    (n=56)
  • Verkazia 2x/day
    (n=54)
  • Cationic ophthalmic emulsion 4x/day
    (n=58)
  • Age (yrs), mean (SD)
  • 9.1 (3.3)
  • 9.6 (3.4)
  • 8.9 (3.2)
  • Percent male
  • 44 (78.6)
  • 44 (77.8)
  • 46 (79.3)
  • Number of patients (%)*
  •  
  •  
  •  
  • VKC grade 3
  • 32 (57.1)
  • 32 (59.3)
  • 40 (69.0)
  • VKC grade 4
  • 24 (42.9)
  • 22 (40.7)
  • 18 (31.0)
  • Number of patients (%)†
  •  
  •  
  •  
  • CFS score 4
  • 42 (75.0)
  • 49 (90.7)
  • 54 (93.1)
  • CFS score 5
  • 14 (25.0)
  • 5 (9.3)
  • 4 (6.9)

CFS=corneal fluorescein staining, SD=standard deviation, VKC=vernal keratoconjunctivitis.

*Graded by Bonini scale.

†Scored by modified Oxford scale.

background
1200ms
Learn more about participants in the VEKTIS study
Learn more about participants in the VEKTIS study

Verkazia delivered significant improvement in other common VKC signs and symptoms in the pivotal trial2,3

  • See results in photophobia

    Photophobia

  • See results in tearing

    Tearing

  • See results in mucous discharge

    Mucous discharge

Select a category

Select a category

  • Photophobia

  • Tearing

  • Mucous discharge

Reductions in photophobia scores from baseline as early as month 12,3

63% mean reduction from baseline in photophobia scores at month 42,3

See reductions in photophobia scores vs baseline over 4 months
See reductions in photophobia scores vs baseline over 4 months

Least squares mean difference based on linear mixed model for repeated measures with treatment, visit, proportion of time within VKC season, baseline, treatment by visit, and patient as covariates.
Each symptom score at each visit was measured using a Visual Analogue Scale (0=no experience of symptom to 100=maximal experience of symptom).

Verkazia effectively treats photophobia

Reductions in tearing scores from baseline as early as month 12,3

66% mean reduction from baseline in tearing scores at month 42,3

See reductions in tearing scores vs baseline over 4 months
See reductions in tearing scores vs baseline over 4 months

Least squares mean difference based on linear mixed model for repeated measures with treatment, visit, proportion of time within VKC season, baseline, treatment by visit, and patient as covariates.
Each symptom score at each visit was measured using a Visual Analogue Scale (0=no experience of symptom to 100=maximal experience of symptom).

Verkazia effectively treats tearing

Reductions in mucous discharge scores from baseline as early as month 12,3

67% mean reduction from baseline in mucous discharge scores at month 42,3

See reductions in mucous discharge scores vs baseline over 4 months
See reductions in mucous discharge scores vs baseline over 4 months

Least squares mean difference based on linear mixed model for repeated measures with treatment, visit, proportion of time within VKC season, baseline, treatment by visit, and patient as covariates.
Each symptom score at each visit was measured using a Visual Analogue Scale (0=no experience of symptom to 100=maximal experience of symptom).

Verkazia effectively treats mucous discharge